Author

Matthew J. Maurer

h-index 20 View on Semantic Scholar

We have 3 of 77 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

A framework to challenge the dogma of incurability in follicular lymphoma.

Follicular lymphoma (FL) has traditionally been considered an incurable malignancy characterized by repeated relapses. However, emerging long-term data are increasingly challenging this paradigm. With rituximab, median overall survival approaches 20 years, and only 35-40% of patients require more than one treatment lin...

L. Magnano, A. López-Guillermo, Matthew J. Maurer · Blood · 0 citations

Open access Sep 2026

Patterns of care, outcomes, and prognostics for transformed follicular lymphoma in the rituximab era.

Histologic transformation (HT) is the leading of death in follicular lymphoma (FL), yet outcomes remain poorly defined due to small cohorts and heterogenous definitions. To characterize outcomes and treatment patterns in the rituximab era we analyzed 344 patients with an initial biopsy-confirmed FL diagnosis between 20...

J. Day, M. Larson, C. Casulo et al. · Haematologica · 0 citations

Open access Aug 2026

Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap.

This White Paper written by the Global Lymphoma Registry Alliance (LyRA) discusses the importance and value of lymphoma registries for different stakeholders as well as benefits of forming a global alliance of the registry network.

Eliza A. Hawkes, E. Chung, M. Bishton et al. · Haematologica · 0 citations